Apixaban safer than rivaroxaban in AF with liver disease, doctors say
Professor James McFadyen said previous NOAC studies excluded patients with cirrhosis and AF.
Doctors can be reassured that apixaban is safe for patients with AF and liver disease, a retrospective cohort study suggests.
The Harvard University-led study found a 38% and 47% higher rate of major haemorrhagic events with warfarin or rivaroxaban, respectively, compared with apixaban, for patients with both cirrhosis and AF.
